Roche's Challenge With Herceptin Gastric Cancer Claim Will Be Companion Dx Use
This article was originally published in The Pink Sheet Daily
Executive Summary
As with Herceptin in breast cancer, the drug is approved simultaneously with a companion diagnostic to measure HER2 levels in gastric cancer patients, but the use of the test is different.